Core Viewpoint - Cognition Therapeutics is advancing the development of zervimesine for treating dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of DLB patients, following positive feedback from the FDA [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related neurodegenerative disorders [8] - The company has completed Phase 2 studies of zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by significant grants from the National Institute on Aging [8] Drug Development - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases, including Alzheimer's and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [6][7] - The Phase 2 SHIMMER study demonstrated zervimesine's positive impact on neuropsychiatric symptoms, showing an 86% slowing of decline on the neuropsychiatric inventory compared to placebo [5] Regulatory Strategy - The company plans to pursue a registrational path for zervimesine based on the strength of Phase 2 data and FDA meeting minutes, aiming to expedite its market entry [2][3] - Cognition expects to meet with the FDA Division of Psychiatry to discuss the DLB psychosis program by mid-2026 [2] Patient Impact - DLB psychosis significantly burdens patients and caregivers, leading to higher healthcare costs and earlier institutionalization, with no approved medications currently available for this condition [4] - Zervimesine has shown a favorable impact on cognitive fluctuations, memory, movement, and daily living activities without impairing motor skills, addressing a critical need for DLB patients [3]

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / March 2, 2026 / Digi Power X Inc. ("Digi Power X" or the "Company") (Nasdaq:DGXX)(Cboe Canada:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier 3 modular data centers powered by owned and controlled energy assets, today pr ...

Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's product candidates, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved treatments currently available [6]. - The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, targets microcystic lymphatic malformations and other skin conditions, while QTORIN™ pitavastatin is aimed at treating disseminated superficial actinic porokeratosis [6].

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,00 ...

Core Insights - Trevi Therapeutics, Inc. is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [3][4] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company [3] - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [3] - Haduvio functions as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in cough control [3] Market Need - There are approximately 150,000 U.S. patients with IPF, with two-thirds experiencing uncontrolled chronic cough [4] - About 228,000 U.S. patients have non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough [4] - Chronic cough can lead to significant morbidity and mortality, including increased respiratory hospitalizations and a decline in quality of life [4] Refractory Chronic Cough (RCC) Insights - RCC affects around 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [5] - RCC is associated with cough reflex hypersensitivity and can severely impact patients' physical, psychological, and social well-being [5] Upcoming Conferences - Trevi will participate in the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, with a fireside chat on March 11 [2] - The company will also be present at the Access USA, Rare Disease Summit 2026 from March 17-19, 2026, with a panel session on March 18 [2]

All figures in Canadian dollars ($) unless otherwise specifiedToronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 2, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced results of the quarter ended December 31, 2025.Summary Financials - Third Quarter Ended December 31, 2025Nine months ...

Customers around the world have been rushing to get in on Nvidia's (NASDAQ: NVDA) artificial intelligence (AI) chips. They are looking for the most powerful tools to develop their programs -- and that leads them to this tech player. Nvidia got in on AI in its earliest days, designing its graphics processing units (GPUs) to suit this market. This gave Nvidia a first-to-market advantage, something it's held onto thanks to its quality products and commitment to innovation. All of this has led to spectacular ...

Vancouver, British Columbia--(Newsfile Corp. - March 2, 2026) - Cordoba Minerals Corp. (TSXV: CDB) (OTCQB: CDBMF) ("Cordoba" or the "Company") is pleased to announce that the shareholders' meeting of JCHX Mining Management Co., Ltd. ("JCHX") have overwhelmingly approved the transaction under the previously announced agreement (the "Amendment Agreement") among Cordoba, Veritas Resources AG ("Veritas") and a consortium of experienced mining investors led by JCHX to amend certain provisions of the definitive ...

Thunder Bay, Ontario--(Newsfile Corp. - March 2, 2026) - Benton Resources Inc. (TSXV: BEX) ("Benton" or the "Company") is pleased to announce its participation at this year's PDAC Convention, where it will host a booth at the Investors Exchange, booth #2117.In addition, Company President and CEO Stephen Stares will be presenting at the Atlantic Canada Day Session on Tuesday, March 3, 2026, at 3:50pm EST at the InterContinental Toronto Centre Hotel - Ontario & Niagara Rooms, located at 225 Front Street West ...

- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be presented a ...